Nafamostat mesylate
Protease inhibitor: Serine proteases. Targets viral cell entry via inhibition of ACE2/TMPRSS2. Gordon et al. bioRxiv, Mar 23 2020, https://doi.org/10.1101/2020.03.22.002386; Wang et al. Cell Res 30:269–271, Feb 4 2020, https://doi.org/10.1038/s41422-020-0282-0; Guy et al. Science, 368 829-830 May 22 2020, https://doi.org/10.1126/science.abb9332.
- Datasheet: view or download
- Applications:Approved drug (Japan) that could be repurposed
Biochemicals & reagents
5668873
1) Han et al. (2019) Identification of nafamostat mesilate as an inhibitor of the fat mass and obesity-associated protein (FTO) demethylase; Chemico-Biological Interactions, 297 80
347.38 ∙ 192.21
Room Temperature
Nafamostat mesylate is a potent and reversible serine protease inhibitor (IC50's range from 0.3 - 54.0 μM) which inhibits the demethylase activity of the fat mass and obesity-associated protein (FTO) (1).